Prevalence of occult hepatitis B virus infection in kidney transplant recipients

Franz, C.P.; Perez, Renata de Mello; Zalis, Mariano Gustavo; Zalona, Ana Carolina Jonard; Rocha, Pedro; Gonçalves, Renato Torres; Nabuco, Leticia Cancella; Villela-Nogueira, Cristiane Alves

doi:10.1590/0074-0276108052013019

Cited by 11 publications

(14 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Confirming this trend, absence or low prevalence of OHB has been the most commonly obtained result in Brazilian studies on different populations, ranging from 0% to 2.7% …”

Section: Discussionsupporting

confidence: 62%

“…Confirming this trend, absence or low prevalence of OHB has been the most commonly obtained result in Brazilian studies on different populations, ranging from 0% to 2.7%. [41][42][43][44][45] In this study, the prevalence of OHB in CRF patients on dialysis was not correlated with gender, age, previous renal transplantation, serological profile for HBV, or the time the patient was on hemodialysis. The only correlation found was related to anti-HCV positivity.…”

Section: Discussioncontrasting

confidence: 49%

See 1 more Smart Citation

Occult hepatitis B among patients with chronic renal failure on hemodialysis from a capital city in northeast Brazil

Fontenele

Gainer²,

Silva

et al. 2015

Hemodialysis International

View full text Add to dashboard Cite

Occult hepatitis B (OHB) is characterized by the presence of HBV-DNA in the absence of HBsAg in the serum of patients. Hemodialysis patients are at high risk for hepatitis B virus and there are few data on the prevalence of OHB in this population, mainly in Brazil. Thus, the aim of this study was to determine the prevalence of OHB in patients undergoing hemodialysis. A cross-sectional study was performed, including 301 patients on chronic hemodialysis at two dialysis centers in São Luís (Maranhão), northeast Brazil. Serological tests were performed for HBsAg, anti-HBc, anti-HBs, and anti-HCV using enzyme immunoassays (ELISA); HBV-DNA and HCV-RNA were studied by real-time PCR. The mean age was 49 ± 15 years, and 128 (42%) were female. Serological tests confirmed that all samples were HBsAg negative. Anti-HBc was positive in 114 (38%) patients, anti-HBc and anti-HBs were simultaneously positive in 104 (35%), and anti-HBc alone was positive in 10 (3%). Tests were negative for anti-HBc and anti-HBs in 55 patients (18%). Anti-HBs was the only positive marker in 132 (44%) patients. Anti-HCV was positive in 15 (5%) patients with HCV-RNA present in 14 of them (93%). HBV-DNA was positive in seven cases (2.3%). There was no association of HBV-DNA with age, gender, time on dialysis, previous kidney transplant, or HBV serological pattern, but there was a positive correlation with the presence of anti-HCV (P < 0.001). OHB in chronic renal failure patients on hemodialysis appears to be a relevant finding, suggesting that studying HBV-DNA in this population using sensitive molecular tests should be a recommended course of action, especially in candidates for renal transplant.

show abstract

“…Confirming this trend, absence or low prevalence of OHB has been the most commonly obtained result in Brazilian studies on different populations, ranging from 0% to 2.7% …”

Section: Discussionsupporting

confidence: 62%

Section: Discussioncontrasting

confidence: 49%

Occult hepatitis B among patients with chronic renal failure on hemodialysis from a capital city in northeast Brazil

Fontenele

Gainer²,

Silva

et al. 2015

Hemodialysis International

View full text Add to dashboard Cite

show abstract

“…78 Data in other types of transplant recipients are less substantial as HBV markers may not be commonly checked in those settings; a report of 207 HBsAgnegative kidney transplant recipients in Brazil showed 1% of them had detectable serum HBV DNA. 79 It was reported that the pre-transplantational prevalence was 2.3% in 217 HBsAgnegative renal transplant recipients in Korea. 80 To prevent OBI in organ transplant recipients, screening of serum HBV DNA in both donors and organ transplant recipients by highly sensitive molecular means would be helpful.…”

Section: Organ Transplantationmentioning

confidence: 99%

Current Knowledge of Occult Hepatitis B Infection and Clinical Implications

Yip

Wong

2019

Semin Liver Dis

View full text Add to dashboard Cite

Occult hepatitis B infection (OBI) is a status of undetectable serum hepatitis B surface antigen (HBsAg) yet detectable serum and/or intrahepatic hepatitis B virus (HBV) DNA. Mutations in the preS1, preS2, and S regions of the HBsAg gene may result in undetectable HBsAg. OBI may either result from a self-limiting acute hepatitis, or in patients with chronic hepatitis B who achieved HBsAg seroclearance, which refers to the loss of detectability of serum HBsAg with or without antibody to HBsAg (anti-HBs) in chronic hepatitis B (CHB) patients. HBsAg seroclearance contributes to a significant proportion of population in seropositive OBI. Both spontaneous and antiviral treatment-induced HBsAg seroclearance rarely happens; yet both types of HBsAg seroclearance are durable. CHB patients who achieve HBsAg seroclearance generally have a favorable clinical course. There is still a low yet definite risk of HCC occurrence, particularly in male CHB patients who achieve HBsAg seroclearance after being 50 years old. Clinical implications of OBI include occurrence of cirrhosis and HCC, liver transplantation, blood products transfusion, hemodialysis, and so on. A potentially life-threatening condition would be OBI reactivation in patients during immunosuppression therapy, especially in the setting of intensified immunosuppression including in onco-hematological patients (those receiving hematopoietic stem cell transplantation and treated with the anti-CD20 monoclonal antibody [e.g., rituximab]). With more new insights into these two conditions, CHB patients who achieved HBsAg seroclearance generally have benign clinical course and good prognosis. Sensitive assay for serum HBV DNA should be considered to establish the presence of OBI in the clinical settings mentioned earlier, which will affect the management plan.

show abstract

“…Although the prevalence of OBI among kidney or bone marrow transplant recipients is controversial, limited data are available on this subject. Franz et al[ 171 ] detected HBV DNA in 1% of 207 kidney transplant recipients negative for HBsAg. Cinzia Lo Giudice et al[ 5 ] detected HBV DNA in a bone marrow transplant recipient who was negative for HBsAg and required constant blood transfusion.…”

Section: Obi and Transplantmentioning

confidence: 99%

Update on occult hepatitis B virus infection

Makvandi¹

2016

WJG

153

147

View full text Add to dashboard Cite

The event of mutations in the surface antigen gene of hepatitis B virus (HBV) results in undetectable hepatitis B surface antigen with positive/negative anti-hepatitis B core (anti-HBc) antibody status in serum and this phenomenon is named occult hepatitis B infection (OBI). The presence of anti-HBc antibody in serum is an important key for OBI tracking, although about 20% of OBI cases are negative for anti-HBc antibody. The diagnosis of OBI is mainly based on polymerase chain reaction (PCR) and real-time PCR assays. However, real-time PCR is a more reliable method than PCR. OBI is a great issue for the public health problem and a challenge for the clinical entity worldwide. The persistence of OBI may lead to the development of cirrhosis and hepatocellular carcinoma. With regard to OBI complications, the screening of HBV DNA by the highly sensitive molecular means should be implemented for: (1) patients with a previous history of chronic or acute HBV infection; (2) patients co-infected with hepatitis C virus/human immunodeficiency virus; (3) patients undergoing chemotherapy or anti-CD20 therapy; (4) recipients of organ transplant; (5) blood donors; (6) organ transplant donors; (7) thalassemia and hemophilia patients; (8) health care workers; (9) patients with liver related disease (cryptogenic); (10) hemodialysis patients; (11) patients undergoing lamivudine or interferon therapy; and (12) children in time of HBV vaccination especially in highly endemic areas of HBV. Active HBV vaccination should be implemented for the close relatives of patients who are negative for OBI markers. Thus, the goal of this review is to evaluate the rate of OBI with a focus on status of high risk groups in different regions of the world.

show abstract

Prevalence of occult hepatitis B virus infection in kidney transplant recipients

Cited by 11 publications

References 17 publications

Occult hepatitis B among patients with chronic renal failure on hemodialysis from a capital city in northeast Brazil

Occult hepatitis B among patients with chronic renal failure on hemodialysis from a capital city in northeast Brazil

Current Knowledge of Occult Hepatitis B Infection and Clinical Implications

Update on occult hepatitis B virus infection

Contact Info

Product

Resources

About